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Abstract
Background: Sponsoring of medical meetings by life science companies has led to reduced participation fees for
physicians but questions potential drawbacks. Ongoing discussions are proposing to ban such sponsoring which
may increase participation fees.
Objectives: To evaluate factors associated with general practitioners’ willingness to pay for medical meetings,
their support of a binding legislation prohibiting sponsoring and their opinion on alternative financing options.
Methods: An anonymous web-based questionnaire was sent to 447 general practitioners’ of one state in
Switzerland, identified through their affiliation to a medical association.
Results: Of the 115 physicians answering, 48% were willing to pay more than what they currently pay for medical
meetings and 79% disagreed that sponsoring introduced a bias in their own prescription practices. In univariate
analyses, factors most associated with physician’s willingness to pay were perception of a bias in peers prescription
practices (OR=6.67; 95% CI: 1.60-27.74), group practice (OR=3.01; 95% CI: 0.94-9.65) and having <4 meetings
with sales representatives per month (OR=2.39; 95% CI: 0.91-6.33). 78% did not support the introduction of a
binding legislation and 56% were in favor of creating a general fund set up by life science companies and centrally
administered by an independent body as an alternative financing option.
Conclusions: Our results suggest that almost half of physicians surveyed were willing to pay more than what
they currently pay for medical meetings and that an independent body that would centrally administer a general fund
set up by life science companies might be better received by general practitioners’ than a legislation banning the
sponsoring of medical meetings by life science companies.
Keywords: Medical education; Ethics; Health policy; General
practice
Abbreviations
CME: Continuing Medical Education; WTP: Willingness to pay
Introduction
Life science companies (e.g., pharmaceutical and health technology
companies) are a very important sector of Switzerland’s economy with
2010 sales representing $57 billion [1]. Not only do they have an
economic benefit but they also provide doctors and patients
worldwide with continual therapeutic progresses. Nevertheless, due to
a few but significant unexpected adverse effects related to the use of
approved drugs (i.e. rofecoxib [2]), and in order to increase patient
security, legal requirements to obtain marketing approval have become
more demanding, resulting in the lengthening of the development
processes and declining research and development productivity [3].
One way life science companies have responded to these challenges
has been by using marketing strategies such as the sponsoring of
physicians’ continuing medical education (CME). This strategy can be
used throughout a products’ life cycle to facilitate product visibility
and utilization, thus representing a marketing strategy with high
return on investment potentials [4,5].
Currently, in Switzerland, physicians have the obligation to acquire
80 annual CME credits. Two-thirds of these CME credits have to be
acquired in the form of structured CME (e.g. medical meetings,
seminars and conferences) while the remaining third can be acquired
through self-study [6]. Most medical meetings are partially or fully
sponsored by life science companies, resulting in lower participation
fees for physicians. Ongoing discussions in the medical literature are
questioning whether this form of industrial marketing does not lead to
potential drawbacks including conflict of interest as well as direct and
indirect commercial products promotion through altered disease
management and prescribing habits bias [7], possibly contributing to
the rise of national health costs [8,9]. This question is even more
relevant in Switzerland, a country with a health care system combining
fee for service and universal health insurance coverage, and where
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national health costs accounted for 10.8% of GDP in 2010 and are
estimated at 11.9% of GDP in 2016 [1].
There are currently no laws in Switzerland regulating the
sponsoring of physicians’ CME. In 2011, a Federal Councillor
proposed to introduce a legislation banning the sponsoring of
physicians medical meetings by life science companies which most
certainly would result in the increase in physicians’ participation fees
[10]. We wanted to evaluate factors associated with general
practitioners (GPs’) willingness to pay (WTP) for medical meetings,




The survey was conducted in the State of Vaud in Switzerland
(721’561 inhabitants estimated at the end of 2011 [11]), where an
anonymous web-based created questionnaire (Survey Methods®, Allen,
Texas) was sent out to 447 GPs’. The 447 GPs were selected based on
their membership to the association of Swiss Family Doctors,
representing the leading association in terms of affiliated physicians’ in
the State of Vaud (convenience sample). The association sent the
hyperlink of the questionnaire and two reminders via their mailing list.
Physicians were free to answer at their convenience between the 13th
July and the 14th August 2011.
Survey questionnaire
A questionnaire comprising a total of 21 questions was developed in
a consensus group based existing questions found in the medical
literature [12-14] and those used by the Swiss Medical Association
(Foederatio Medicorum Helveticorum, FMH) for their statistics. The
questionnaire was pilot tested with 10 chief residents from the
Department of Ambulatory Care and Community Medicine of the
University of Lausanne (State of Vaud) and with 10 GPs’ from other
French-speaking States (Fribourg, Neuchatel and Valais) to evaluate
the overall comprehension of the questions and to test the relevance of
our questions (face validity). Two questions were modified based on
the pilot test of the questionnaire. The 10 chief residents and the 10
GPs’ who participated in the pilot test were not part of the study
population when the study was conducted.
The first part of the questionnaire determined physicians’
socioeconomic characteristics using multiple choice questions. The
questionnaire then targeted three main areas: (1) physicians’ WTP for
CME, (2) physicians’ position on the sponsoring of CME by life
science companies and (3) physicians’ opinion on alternative financing
options to support their CME. Physicians’ WTP was evaluated using
two types of questions. An open-ended question was used to quantify
their global WTP for half a day of CME (4 hours of CME equivalent to
4 credits) and a multiple choice question was used to evaluate their
WTP for half a day of each CME category with 5 possible answers (i.e.,
“≥CHF150”, “CHF100-149”, “CHF50-99”, “<CHF50”, “I am not
prepared to pay for this category of CME”; 1CHF=1EUR [15]). We
also used an open-ended question to quantify physician’s perception
of a two-day non-sponsored medical meeting participation fee given
the participation fee of EUR310 to attend the two-day sponsored
medical meeting of Swiss Family Docs, a highly attended sponsored
medical meeting for Swiss GPs. Their opinion on the other items was
evaluated using a four-point scale (i.e., 4 representing “strongly agree”
and 1 “strongly disagree”).
Analysis
Simple descriptive statistics were used to illustrate physicians’
socioeconomic characteristics and to describe physicians’ collective
opinion on their WTP for CME, their perception of a bias in
prescription practices induced by commercial support, their support
of a binding legislation and their opinion on alternative financing
options. To evaluate factors associated with physicians’ WTP for
medical meetings, WTP was dichotomised into EUR ≥150 and EUR
<150, EUR ≥150 representing the category of physicians willing to pay
the highest fees for medical meetings based on the 5 possible answers
to our multiple choice question evaluating physicians’ WTP for each
CME category. Univariate logistic regression analyses were ran with
WTP for medical meetings as the outcome. Variables tested were age,
sex, full-time/part-time, annual income, practice location, practice
structure, health maintenance organization membership, number of
meetings with sales representatives per month, average time spent per
meeting, number of sponsored medical meetings attended in 2010,
perception of a bias in own prescription practices induced by
commercial support and perception of a bias in peers prescription
practices induced by commercial support (i.e. some responding GPs’
felt some of their peers prescribing habits could be influenced by
attending sponsored meetings). These variables were chosen in a
consensus group and using those tested in the medical literature
[11-13]. Statistical analyses were performed using Stata version 12
(Stata Corporation, TX).
Ethics
The study protocol was approved by the ethics committee of the
University of Lausanne, Switzerland, decision number 52/13.
Information concerning this study was disclosed by email to




Of the 447 physicians contacted, 115 questionnaires (N=115) were
completed through the online survey (response rate of 26%). A
majority of the respondents were male (72%) with a mean age of 53
years 6 (Table 1). 52% of physicians worked part-time (4% worked 5
half days or less per week and 48% worked in between 6 and 9 half
days per week). Annual income before tax was less than EUR160’000
for 63% of physicians. The majority (53%) of physicians working full-
time earned ≥EUR160’000 and 63% of physicians working part-time
earned in between EUR80’000 and EUR159’999. Their practices were
majorly located in small towns (41%) followed by rural villages (35%)
and large cities (24%). 63% worked in group practices and 30% were
member of a health maintenance organization. 56% of physicians met
up with sales representatives ≥4 times per month and 64% spent 15
minutes or less per meeting. 35% of physicians did not attend any
sponsored medical meetings in 2010 in comparison with 33% who
attended 1 to 3 sponsored medical meetings and 34% who attended 4
sponsored medical meetings or more.
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Physicians’ WTP for CME
The mean (±SD) WTP was EUR105 (±71) for half a day of CME
(e.g. medical meetings, seminars and conferences), 27% of physicians
were willing to pay ≥EUR150, 34% were willing to pay in between
EUR100 and EUR149 and 39% were willing to pay <EUR100 for half a
day of CME (Figure 1). 48% of physicians were willing to pay
≥EUR100 for medical meetings (18% were willing to pay EUR≥150
and 30% were willing to pay in between EUR100 and EUR149) with
medical meetings being an important category of CME for 96% of
physicians.
We also assessed physician’s cost estimate of a two-day medical
meeting that would not be sponsored by life science companies. The
mean (±SD) cost estimate was EUR799 (±312), corresponding to an
increase of 58% in comparison to Swiss Family Docs’ current
participation fee of EUR310.




53 (8)  53
Sex    
Male 83 72% 68%
Female 32 28% 32%
Full-time/part-time*    
Full-time 55 48% 43%
Part-time 60 52% 57%
Income per year    
EUR<160’000 72 63% 37%
EUR≥160’000 43 37% 63%
Practice location**    
Large city 28 24% n.a.
Small town 47 41% n.a.
Rural village 40 35% n.a.
Practice structure    
Group 72 63% 43%




   





   
0 12 10% n.a.
1-3 39 34% n.a.
4-10 56 49% n.a.





   
<16 minutes 74 64% n.a.




   
0 40 35% n.a.
1-3 38 33% n.a.
4-10 29 25% n.a.
≥11 8 7% n.a.
Table 1: Physicians’ socioeconomic characteristics.
Abbreviation of FMH: Foederatio Medicorum Helveticorum (Swiss
Medical Association), n.a.: non-available.
*Part-time: corresponds to an activity rate of 9 half days or less.
**Large city: ~130’000 inhabitants, small town: ~18’000 inhabitants
and rural village: ~3’000 inhabitants.
***Health maintenance organizations are managed care plans that
provide health care services to their members through networks of
doctors, hospitals, and other health care providers. (Source: Texas
Department of Insurance, http://www.tdi.texas.gov/pubs/consumer/
cb069.html, accessed at 20.08.2013).
Figure 1: Self-reported physicians’ willingness to pay (WTP) for
half a day of continuing medical education* (CME).
Variables associated with physicians’ WTP for medical
meetings
The univariate logistic regression showed three variables associated
with physicians’ WTP ≥EUR150 for medical meetings (all p<0.1): the
perception of bias in peers prescription practices, “strongly agree” vs.
“agree, disagree, or strongly disagree” (OR=6.67; 95%CI: 1.60-27.74);
the practice structure, group vs. individual (OR=3.01; 95%CI:
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0.94-9.65); and the number of meetings with sales representatives per
month, <4 vs. ≥4 (OR=2.39; 95%CI: 0.91-6.33) (Table 2).
Physicians’ position on the sponsoring of CME
79% of physicians disagreed that sponsoring of their CME by life
science companies influenced their own prescription practices and
61% disagreed that it introduced a bias in their colleagues’ prescription
practices. In terms of introducing a binding legislation prohibiting the
sponsoring of CME by life science companies, 78% of physicians
would not support it and 77% did not think that such draft legislation
was likely to be enacted.
Variable OR (95% CI) p-value
Perception of bias in peers prescription
practices*
6.67 (1.60-27.74) 0.01
Group practice structure 3.01 (0.94-9.65) 0.06
<4 meetings with sales representatives
per month
2.39 (0.91-6.33) 0.08
Annual income ≥EUR160’000 2.13 (0.82-5.55) 0.12
<16 minutes spent per meetings with
sales representatives
1.99 (0.67-5.89) 0.22
Male sex 1.80 (0.56-5.84) 0.33
≥4 sponsored medical meetings
attended in 2010
1.77 (0.67-4.67) 0.25
Working Full-time 1.58 (0.61-4.11) 0.35
Perception of a bias in own prescription
practices*
1.50 (0.15-15.18) 0.73
Practice located in small towns or rural
villages
1.46 (0.45-4.76) 0.53
Not member of a health maintenance
organization
1.12 (0.39-3.17) 0.84
Age 1.02 (0.96-1.07) 0.61
Table 2: Factors associated with physicians’ willingness to pay (WTP)
for medical meetings in univariate logistic regression models.
Abbreviations: OR, odds ratio; CI, confidence interval.
*Perception of bias in peers prescription practices dichotomized as
“strongly agree” vs. “agree, disagree, strongly disagree” on a 4 item like
rt scale.
Physicians’ opinion on alternative financing options
A majority of physicians were in favour of a financing through a
levy on medical services (65%) instead of direct sponsorship to
support CME. 56% were in favour of financing through a general fund
set up by life science companies and centrally administered by an
independent body, 55% agreed to government financing and 65% were
unfavourable to self-funding by physicians (Figure 2).
Figure 2: Physicians’ opinion on alternative financing options.
Discussion
Our study shows that 48% of GPs’ in the surveyed population were
willing to pay ≥EUR100 for half a day of medical meetings, a category
of CME that 96% of surveyed physicians rated as important. Given the
current participation fee of 80EUR for half a day of medical meeting,
our results suggest that physicians are willing to pay more than what
they currently pay for medical meetings. Variables associated with
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physicians’ WTP for medical meetings in univariate analyses, i.e. a
WTP ≥EUR150, were perception of the influence of bias in peers’
prescription practices, group practice structure and <4 meetings with
sales representatives per month.
An on CME site survey study conducted by Tabas et al. in the US
found that 42% of medical professionals (physicians, nurses, nurse
practitioners and physician assistants) were willing to pay higher fees
to decrease or eliminate commercial support, 88% believed that
commercial support introduced a bias and 85% did not support the
elimination of commercial support from CME activities [16]. Our
study adds to previous work by quantifying physicians’ WTP for CME
and highlights characteristics associated with physicians’ WTP for
medical meetings.
Prior studies have shown that life science companies influence
physicians prescribing habits in ways that physicians do not recognize.
Indeed, physicians feeling valued by life science companies often
unconsciously reciprocate this valorisation by using their therapeutic
products [17]. In our survey, 56% of physicians meet up with sales
representatives four times or more per month. Furthermore, 79% of
physicians disagreed that sponsoring influenced their own prescribing
habits and 61% of physicians disagreed that sponsoring influenced
their colleagues prescribing habits demonstrating an optimistic bias.
Therefore, physicians’ empowerment through prescribing bias
awareness and independent decision making skills would potentially
help physicians manage their collaboration with life science
companies. This could not only help reduce potential influence of life
science companies on physicians without modifying current
sponsoring, but it could also possibly increase physicians WTP for
medical meetings. Physicians who see sales representatives more often
tend to be those who are more isolated from their colleagues [18].
Tentative explanations, although not tested in our analyses, would be
that physicians in group practice rely less on sales representatives to
learn about novel drugs or that they go through more peer pressure
not to meet up with sales representatives. Given the current trend
towards an increase in group practice structures [19], there might be
an increase in physicians WTP for medical meetings in the future and
a shift in the way physicians value their CME from a model relying on
sales representatives to a model relying on medical meetings and
group learning.
Although 78% of physicians were not in favour of a legislation
prohibiting the sponsoring of medical meetings by life science
companies, physicians agreed to a levy on medical services (65%), a
general fund set up by life science companies and centrally
administered by an independent body (56%) and government
financing (55%). Both a levy on medical services and government
financing would increase national health costs already accounting for
11.7% of GDP in 2011 [1]. The alternative of a general fund therefore
seems the most appropriate option to begin with. Nevertheless, this
proposition would need to have an acceptable return on investment
for life science companies to adhere to this alternative sponsoring
option. Further research assessing life science companies’ opinion
needs to be undertaken.
Unlike the US where the question of CME sponsoring by life
science companies and conflict of interest issues have been addressed
for over 30 years [20] and regulated by the Sunshine Act, the situation
in Switzerland is still in its early stages, possibly explaining low
prescription bias perception found in our study. Currently, there are
very few discussion and no laws that regulate the sponsoring of CME
by life science companies. Recommendations on the collaboration
between the medical cooperation and life science companies were
edited for the first time in 2002 by the Swiss Academy of Medical
Sciences (SAMS). These recommendations now stand as guidelines for
physicians to obtain their 50 annual mandatory structured CME
credits. A seven criteria checklist is used to ensure objectivity and
transparency of a medical meeting for its credits to be validated as
CME [21].
Several limitations must be taken into account when assessing the
implications of our findings. The response rate was low, potentially
limiting the validity of our findings, and we involved physicians from
one State of Switzerland which had also to be part of the association of
Swiss Family Doctors; thus generalization to all GPs’ in Switzerland
may be erroneous. However, despite these limitations, the
socioeconomic characteristics of the surveyed physicians are similar to
those of the Swiss Medical Association (Foederatio Medicorum
Helveticorum, FMH), representing the target population; except for
income per year and practice structure. CME requirement and
programs vary amongst different specialties, making our observations
difficult to generalize to other medical specialities. The survey relied
on self-reported behaviour, potentially misestimating reality. Further
studies should be undertaken to investigate physicians’ WTP on a
national basis in order to confirm our conclusions.
Conclusion
In conclusion, this study shows that almost half of general
practitioners were willing to pay more than what they currently pay
for medical meetings and that most respondents did not agree that
sponsoring induced prescribing bias. For decision makers willing to
regulate the mutual dependence of physicians and life science
companies, rather than a legislation banning the sponsoring of
medical meetings by life science companies which would increase
physicians participation fees, an independent body that would
centrally administer a general fund set up by life science companies to
various medical meetings might be better received by surveyed
physicians whilst maintaining health costs at an affordable level.
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